DENTSPLY SIRONA (NASDAQ:XRAY) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS

DENTSPLY SIRONA (NASDAQ:XRAY) issued its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01), FiscalAI reports. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA updated its FY 2026 guidance to 1.400-1.500 EPS.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock traded up $0.17 during midday trading on Tuesday, hitting $11.37. 9,461,481 shares of the company were exchanged, compared to its average volume of 4,462,574. The firm has a market capitalization of $2.28 billion, a P/E ratio of -3.79, a PEG ratio of 1.39 and a beta of 0.93. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The firm’s 50 day moving average price is $12.16 and its two-hundred day moving average price is $12.03. DENTSPLY SIRONA has a 52 week low of $9.85 and a 52 week high of $17.18.

Insider Activity

In related news, Director Gregory T. Lucier bought 15,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 9th. The stock was acquired at an average price of $12.45 per share, with a total value of $186,750.00. Following the acquisition, the director owned 65,000 shares of the company’s stock, valued at approximately $809,250. This represents a 30.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James D. Forbes bought 5,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average cost of $12.48 per share, with a total value of $62,400.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $124,800. This trade represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 70,000 shares of company stock valued at $956,437 in the last ninety days. 0.52% of the stock is currently owned by insiders.

Institutional Trading of DENTSPLY SIRONA

A number of institutional investors have recently bought and sold shares of the business. Daiwa Securities Group Inc. boosted its holdings in DENTSPLY SIRONA by 2.9% in the 4th quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after purchasing an additional 767 shares during the period. Empowered Funds LLC boosted its holdings in DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares during the period. Wilmington Savings Fund Society FSB boosted its holdings in DENTSPLY SIRONA by 13.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 13,055 shares of the medical instruments supplier’s stock valued at $149,000 after purchasing an additional 1,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA in the 1st quarter valued at about $26,000. Finally, Brevan Howard Capital Management LP boosted its holdings in DENTSPLY SIRONA by 9.9% in the 2nd quarter. Brevan Howard Capital Management LP now owns 20,002 shares of the medical instruments supplier’s stock valued at $318,000 after purchasing an additional 1,800 shares during the period. Institutional investors own 95.70% of the company’s stock.

Analyst Ratings Changes

XRAY has been the topic of several recent analyst reports. Robert W. Baird boosted their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Citigroup initiated coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Monday, April 20th. Barrington Research boosted their price objective on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Finally, Wells Fargo & Company boosted their price objective on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.91.

DENTSPLY SIRONA News Roundup

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Revenue beat and operating improvements — Q1 net sales came in at $880M (above consensus), with adjusted gross margin of 50.7% and adjusted EBITDA margin of 14.7%, showing margin progress that supports cash flow and longer‑term profitability. Dentsply Sirona Q1 Results
• Positive Sentiment: New product and commercial traction — launched Smart View‑Detect (FDA cleared, CE marked) — the company is also expanding distribution (Atlanta Dental Supply) and reported initial CEREC installs under the Benco agreement, which can drive adoption of higher‑margin connected technology. Distribution Expansion
• Positive Sentiment: Capital allocation focus — management said it will prioritize debt reduction, liquidity management and working‑capital improvement, which may de‑risk the balance sheet and support valuation over time. Q1 Results
• Neutral Sentiment: FY‑2026 guidance roughly in line — management set EPS guidance of $1.40–1.50 (consensus ~1.43) and revenue guidance of $3.5–3.6B (slightly below some estimates). Guidance keeps expectations intact but leaves limited upside. Guidance Slide Deck
• Negative Sentiment: Small EPS miss and GAAP loss — adjusted EPS was $0.27 (missed consensus by $0.01) and GAAP net loss per share was ($0.05); company still shows a negative net margin on a GAAP basis, signaling near‑term profitability headwinds. Q1 Results
• Negative Sentiment: Analyst tone and macro/headwind reminders — brokers on average rate the stock a “Hold” and pre‑earnings commentary highlighted U.S. softness, tariff pressure and transformation costs that could constrain near‑term margin recovery. Brokerage Coverage

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.